AstraZeneca PLC (LON:AZN) Stock Has Consensus Target Price of £153.57

AstraZeneca PLC (LON:AZN) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is £153.57.

A number of research analysts have commented on AZN shares. Berenberg Bank reaffirmed a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £117 target price on shares of AstraZeneca in a report on Tuesday, September 29th. Citigroup raised their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Friday, October 30th. Finally, Royal Bank Of Canada assumed coverage on AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating and a £145 price objective for the company.

Insider Buying and Selling at AstraZeneca

In other news, insider Michel Demare purchased 2,500 shares of the stock in a transaction dated Monday, September 14th. The shares were bought at an average cost of £121.21 per share, for a total transaction of £303,025. Company insiders own 0.15% of the company’s stock.

AstraZeneca Trading Up 0.7%

LON AZN opened at £141.18 on Thursday. The company’s 50-day simple moving average is £124.04 and its two-hundred day simple moving average is £134.27. The company has a debt-to-equity ratio of 66.10, a quick ratio of 0.59 and a current ratio of 1.01. AstraZeneca has a one year low of £114.04 and a one year high of £157.32. The company has a market capitalization of £218.96 billion, a price-to-earnings ratio of 21.13, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.